

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

GlaxoSmithKline LLC,  
Petitioner

v.

FibroGen, Inc.,  
Patent Owner

U.S. Patent No. 8,466,172  
Appl. No. 12/928,119 filed Dec. 2, 2010  
Issued: June 18, 2013

Title: Stabilization of Hypoxia Inducible Factor (HIF) Alpha

---

IPR Trial No. IPR2016-01315

**CERTIFICATE OF SERVICE**

**Re: CORRECTED/MISSING EXHIBIT**

## **CERTIFICATE OF SERVICE**

I hereby certify that true and corrected copy of the foregoing Missing Exhibit 1046 re: Petition for *Inter Partes* Review of U.S. Pat. No. 8,466,172 was served on July 14th, 2016 via UPS Overnight service to the correspondence address for FibroGen, Inc, Address and Attorney of Agent listed for the '172 patent as evidenced in Public PAIR on June 28, 2016 at the address listed below

General Counsel  
FibroGen, Inc.  
409 Illinois Street  
San Francisco, CA 94158

Dated: July 14th, 2016

/s/ Brian W. Nolan  
Brian W. Nolan, Reg. No. 45,821  
Attorney for Petitioner GlaxoSmithKline LLC